VIVUS, Inc. (VVUS): Obesity Drug Finally Hits Pharmacies
After gaining Food and Drug Administration approval nearly a year ago, patients can finally walk into a pharmacy and get their prescription for VIVUS, Inc.
Posts Tagged ‘Vivus Inc. (VVUS)’
Galena Biopharma Inc (GALE): Should You Buy the Hype Surrounding This Product Launch?
While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success.
Elan Corporation, plc (ADR) (ELN), VIVUS, Inc. (VVUS), MannKind Corporation (MNKD): Three Biotech Companies to Watch This Summer
The news flow from biotech companies might slow down during the summer, but it won't stop.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Payday on the Way for America’s New Epidemic Disease?
If that word is "disease," it could be billions of dollars. The American Medical Association, or AMA, recently decided to categorize obesity as a disease.
VIVUS, Inc. (VVUS), ISIS Pharmaceuticals, Inc. (ISIS), Gilead Sciences, Inc. (GILD): Biotech Companies Battle It Out
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Pfizer Inc. (PFE), VIVUS, Inc. (VVUS): Cheap Viagra That Americans Can’t Buy
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
VIVUS, Inc. (VVUS): Qsymia Just Won The Lotto
After almost a decade, the FDA has once again started approving obesity drugs. VIVUS, Inc. (NASDAQ:VVUS)’s Qysmia and Arena Pharmaceuticals, Inc.
Pharma News: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & ACADIA Pharmaceuticals Inc. (ACAD)
Editor's Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc.
VIVUS, Inc. (VVUS): An Obese Proxy Fight
Proxy fights are like the demolition derby of the investment world.
Ariad Pharmaceuticals, Inc. (ARIA), VIVUS, Inc. (VVUS): Winning Biotech Investment Strategies and Their Potential Pitfalls
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Aegerion Pharmaceuticals, Inc. (AEGR), Arena Pharmaceuticals, Inc. (ARNA): Investment Opportunities in Drug Launches
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Weight Loss Drug Sweepstakes
First investors were reminded of the struggle between VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc.
Why I’m Buying Weight Watchers International, Inc. (WTW)
A historic view of recurring themes in major wartime conflicts, our puzzling tendency to continuously overeat, and the pie-in-the-sky popularity of Charles Duhigg's The Power ...
3 VIVUS, Inc. (VVUS) Metrics To Be Aware Of
In the financial blogosphere, there are lots of tools for VIVUS, Inc. (NASDAQ:VVUS) readers to track, but it's smart to be aware of a stock's short interest.
Sarepta Therapeutics Inc (SRPT), VIVUS, Inc. (VVUS): The Week’s Biotech Winner and Loser
The easiest route would involve the companies with the biggest share price movements.
What to Expect From Arena Pharmaceuticals, Inc. (ARNA)’s Launch of Belviq
After years of anticipation by doctors, patients, and investors, Belviq was finally launched last week for treatment of obesity, type 2 diabetes and overweight patients with a...
Arena Pharmaceuticals, Inc. (ARNA) News: Positive Rating, Anti-Obesity Drug, Post-Launch Presentation & More
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc.
Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease
The decision wasn't without debate, though. In fact, the AMA's Council on Science and Public Health actually recommended against calling obesity a disease.
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Consumer Reports Says “Exercise” Rather Than Take This Drug
The U.S. weight loss market is estimated at $61 billion, with the global weight management market expected to be $650 billion by 2015.
Onyx Pharmaceuticals, Inc. (ONXX), Arena Pharmaceuticals, Inc. (ARNA): The Top 5 Diseases Caused by Obesity
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from...
Arena Pharmaceuticals, Inc. (ARNA): An Obesity Drug Stock to Fatten your Portfolio?
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): New Obesity Drug Hits the Market
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)' Belviq, the newest offering, looks relatively safe.
Johnson & Johnson (JNJ), VIVUS, Inc. (VVUS): The Three Biggest Risk Factors for a Stroke
Often referred to as "the silent killer," stroke is the fourth-leading cause of the death in the U.S., behind only heart disease, cancer, and chronic lower respiratory diseases...
Sarissa’s Stake in Vivus, Inc. (VVUS) Points to Renewed Interest in the Company
Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS) .
Pfizer Inc. (PFE)’s Big Chance
When we think of big pharma companies, the company we think about constantly is Pfizer Inc.
Santarus, Inc. (SNTS): Insiders Are Buying, Should You?
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): The 7 Most Obese U.S. States
The U.S., which ranks as the most obese nation in the world according to the Organization for Economic Cooperation and Development, has seen a relatively steady increase over ...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): This Obesity Drugmaker Is Badly In Need of a Marketing Partner
As recently as a decade ago, the biggest hurdle for biotech companies wasn't competition from their peers or even the sale price of their drugs.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Are NOT The Newest Obesity Drug Player
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Three Big Reasons to Own Johnson & Johnson (JNJ) Stock
When investors are looking to fill out their retirement portfolios, they would be wise to give a long, hard look at Johnson & Johnson (NYSE:JNJ) stock.
Dunkin Brands Group Inc (DNKN), McDonald’s Corporation (MCD): The Seven Least Obese U.S. States
With the Organisation for Economic Co-operation and Development pinpointing the United States as the most obese country in the world, it can be hard to find many positives with...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): The Top Three Causes of Diabetes
A whopping 25.3 million people in the U.S. right now are diabetic, with an additional 79 million Americans in the pre-diabetes stage.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Why This Obesity Drug Is the Sector’s Best Bet
Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive.
Hedge Fund News: Louis Bacon, Dell Inc. (DELL), The Procter & Gamble Company (PG)
Are macro funds finally staging a comeback this year? After posting disappointing numbers in 2012 -- when the average macro-focused hedge fund fell by 0.40 percent, according ...
Arena Pharmaceuticals, Inc. (ARNA): Why This Obesity Drug Is the Sector’s Best Bet
The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals, Inc.
Orexigen Therapeutics, Inc. (OREX), And Three Pipeline Obesity Treatments You Should Watch
Obesity is a growing pandemic for many industrialized nations, especially in the U.S., where it now affects almost 36% of adults and 17% of adolescents.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ): The Surprising Link Between ADHD and Obesity
The study tracked men with ADHD for more than 30 years and found that a whopping 41% of them were obese compared to 22% of patients in a matched control group who didn't have ...
Whole Foods Market (WFM), Chipotle Mexican Grill, Inc. (CMG): The 9 Most Obese Countries in the World
The rate of worldwide obesity has been marching higher at an extraordinary rate for more than three decades now.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): What To Know About Obesity
The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in June 2012.
Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS) & Orexigen Therapeutics, Inc. (OREX): What’s Weight Loss For Now?
It wasn't that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle
Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) -- mere weeks before a competing drug from Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (ARNA): The Mystery Objectors
Short interest in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is 28.81% of its float.
Arena Pharmaceuticals, Inc. (ARNA): You Need To See These 5 Points
A sharp drop in Arena Pharmaceuticals (NASDAQ:ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application (“MAA”) ...
VIVUS, Inc. (VVUS): Is It Really Time To Sell?
Biotech company VIVUS, Inc. (NASDAQ:VVUS) has struggled to pick up sales of its obesity medication Qsymia since the drug was launched in September.
VIVUS, Inc. (VVUS): You’ve Got To Spend Money To Make Money
VIVUS, Inc. (NASDAQ:VVUS) has the first part down.
Pfizer Inc. (PFE), Johnson & Johnson (JNJ): The Next Frontier?
Only 19 drugs have ever netted at least $5 billion in annual sales -- and most were at their peak --according to a list compiled by Simon King of Forbes earlier this year.
